Myeloperoxidase (MPO) inhibitor verdiperstat was no better than placebo in the M-STAR trial in patients with MSA, and looks likely to be abandoned for this indication.
It’s not the end of the line for the drug, which Biohaven picked up in 2018, after it was shelved by AstraZeneca despite reaching the phase 2 trial stage in Parkinson’s disease and MSA.
Biohaven is still running a phase 2/3 trial of the MPO inhibitor in amyotrophic lateral sclerosis (ALS), another neurodegenerative disease, that is due to complete enrolment later this year.
